Sernova ( (TSE:SVA) ) has provided an announcement.
Sernova Corp. has rescheduled its annual general and special meeting of shareholders to January 10, 2025, due to a postal strike in Canada, ensuring compliance with regulatory requirements for distributing meeting materials. The company remains focused on advancing its Cell Pouch technology as a potential revolutionary treatment platform, reinforcing its position in the regenerative medicine industry.
More about Sernova
Sernova Corp. is a clinical-stage regenerative medicine company focused on developing the Cell Pouch bio-hybrid organ, aiming to provide functional cures for chronic diseases such as type 1 diabetes and thyroid disorders. The company’s innovative approach integrates living cells with non-living materials to mimic natural organ functions.
YTD Price Performance: -2.17%
Average Trading Volume: 110,628
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$73.91M
For detailed information about SVA stock, go to TipRanks’ Stock Analysis page.